AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye

Molecular Therapy, Vol. 25, No 12, DOI: http://dx.doi.org/10.1016/j.ymthe.2017.08.018
Molecular Therapy, online article

Ocular gene therapy has evolved rapidly into the clinical realm due to promising pre-clinical proof-of-concept studies, recognition of the high unmet medical need of blinding disorders, and the excellent safety profile of the most commonly used vector system, the adeno-associated virus (AAV). With several trials exposing subjects to AAV, investigators independently report about cases with clinically evident inflammation in treated eyes despite the concept of ocular immune privilege. Here, we provide a detailed analysis of innate and adaptive immune response to clinical-grade AAV8 in non-human primates and compare this to preliminary clinical data from a retinal gene therapy trial for CNGA3-based achromatopsia (ClinicalTrials.gov: 02610582).

TU München
Helmholtz München
MPI of Neurobiology
MPI of Biochemistry